8-K: Assure Holdings and Danam Health Announce Merger Plans, Aiming for Nasdaq Listing

Assure Holdings and Danam Health are merging, with Danam becoming a wholly-owned subsidiary of Assure, shifting focus to pharmaceutical and healthcare services.

Summary

• Assure Holdings Corp. is merging with Danam Health, Inc., with Danam becoming a wholly-owned subsidiary of Assure.
• The merger is a strategic move by Assure after evaluating several M&A candidates due to declines in medical reimbursement rates.
• Following the merger, former Assure equity holders are expected to own approximately 10% of the combined company, while Danam equity holders will own about 90%.
• The combined company will focus on pharmaceutical and healthcare services, leveraging Danam's technology platform, specialty pharmacy, and wholesale operations.
• Danam Health distributed $35 million of pharmaceutical products in 2023 and has over 50 employees.
• The total addressable market for the combined company is estimated at $430 billion, with a serviceable market of $180 billion.
• Assure is seeking shareholder approval for the merger in the second calendar quarter of 2024 and aims to close the transaction before July 22, 2024.
• Assure has already sold its clinical assets to MPower on March 26, 2024.

Sentiment

Score: 5

Explanation: The document outlines a significant strategic shift for Assure, but the dilution for existing shareholders and the abandonment of the previous business model temper the positive aspects of the merger. The future success of the combined entity is uncertain.

Positives

• The merger provides Assure with a new strategic direction in the pharmaceutical and healthcare services sector.
• Danam Health has a strong existing business with $35 million in pharmaceutical product distribution in 2023.
• The combined company has a large total addressable market of $430 billion.
• Danam's platform includes a digital pharmacy, clinical concierge services, and wholesale distribution, offering a comprehensive solution.
• The merger is expected to allow the combined company to meet Nasdaq listing requirements.

Negatives

• Assure shareholders will experience significant dilution, owning only approximately 10% of the combined company.
• Assure's previous business model of providing IONM services has been effectively abandoned.
• The merger is subject to shareholder approval and other closing conditions, creating uncertainty.
• There are risks associated with integrating the two companies and achieving the anticipated benefits.

Risks

• The merger may not be completed if conditions are not met, including shareholder approval.
• There are uncertainties regarding the timing of the merger and the ability of both companies to complete the transaction.
• Assure faces risks in managing operating expenses and merger-related costs.
• The combined company may not be able to obtain sufficient capital to advance its business plan.
• There is a risk that the anticipated benefits of the merger may not be realized.
• Adjustments to the exchange ratio could alter the ownership percentages of Assure and Danam shareholders.
• The market price of Assure's common stock could be negatively impacted.

Future Outlook

The combined company will focus on pharmaceutical and healthcare services, leveraging Danam's existing platform and aiming for a Nasdaq listing. The merger is expected to close before July 22, 2024, pending shareholder approval and other conditions.

Management Comments

• Management was requested to present options to retain value in the public vehicle and disposal of the clinical operations and related assets.
• Management reviewed and assessed seventeen M&A candidates choosing Danam Health, Inc. (Danam) as the merger candidate.

Industry Context

This merger reflects a strategic shift for Assure from healthcare services focused on IONM to the pharmaceutical and healthcare services sector, aligning with broader trends in healthcare consolidation and diversification. The move to integrate technology and pharmacy services is also a growing trend in the industry.

Comparison to Industry Standards

• The merger of Assure and Danam is similar to other healthcare companies seeking to diversify their revenue streams and expand their market reach.
• Danam's focus on a digital pharmacy platform and wholesale distribution is comparable to companies like Amazon Pharmacy and GoodRx, which are leveraging technology to disrupt traditional pharmacy models.
• The move to integrate technology and pharmacy services is a growing trend in the industry, with companies like CVS Health and Walgreens also expanding their digital offerings.
• The estimated $430 billion total addressable market is significant, but the combined company will need to compete with established players in the pharmaceutical and healthcare services sector.

Stakeholder Impact

• Assure shareholders will experience significant dilution in their ownership.
• Danam shareholders will gain a majority stake in the combined company.
• Employees of both companies may experience changes as the businesses integrate.
• Customers of both companies may see changes in the services offered.
• The merger could impact suppliers and other business partners of both companies.

Next Steps

• Assure will seek shareholder approval for the merger in the second calendar quarter of 2024.
• The companies plan to close the transaction before the Nasdaq panel deadline of July 22, 2024.
• The combined company will work to integrate the two businesses and execute its new strategy.

Key Dates

Keywords

merger, pharmaceutical, healthcare services, Danam Health, Assure Holdings, Nasdaq, digital pharmacy, wholesale distribution, IONM, shareholder approval